Biopharma buyouts still pricey
A global pandemic has done nothing to crimp M&A premiums, with acquirers forced to swallow ever higher price tags.
Gilead rescues biopharma’s takeout scene
A few multi-billion-dollar deals got done in the third quarter, but 2020’s acquisition scene still looks anaemic.
Biopharma takeovers show quantity, if not quality
Second-quarter deal values plummeted as Covid-19 spread and the prices of target companies spiralled.
Big pharma sports smallest late-stage pipeline for a decade
The number of novel, pivotal-stage projects in big pharma pipelines has plunged – just as Covid-19 put the brakes on deal making.
Biopharma acquisitions slow, but it's not Covid-19's fault yet
Drug makers struck few M&A deals in the first quarter, but activity did not dry up, suggesting that the real impact of coronavirus has yet to play out.
Biopharma’s big bet on cancer is laid bare
Drug developers have directed almost half of their dealmaking firepower at oncology projects over the past five years, with cardiovascular a distant second.
A thoroughly average year for medtech mergers
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.
What makes a great year for takeovers?
The number of biopharma buyouts overall last year did not rise, though more deals were struck in the “sweet spot”, and premiums saw a healthy rise.
